Carl Ward, a postdoctoral researcher in the Marson Lab, led much of the computational work for the study.
Carl Ward, a postdoctoral researcher in the Marson Lab, led much of the computational work for the study.
Tyler O'Neal, Staff Editor BIOLOGY

Unlocking the secrets of human biology with computational genomics, next-gen CRISPR

Advancements in technology have opened up exciting possibilities in understanding the intricate workings of the human body. One such breakthrough is the use of computational genomics, paired with next-generation CRISPR technology, to create an unprecedented molecular map of the human genome. This groundbreaking research, led by scientists at Gladstone Institutes, has the potential to unlock the secrets of human biology and pave the way for new treatments and cures for diseases.

CRISPR is a revolutionary tool that allows scientists to precisely edit genes. It essentially acts as a pair of "molecular scissors" that can target specific areas of the genome and make precise changes, such as removing, adding, or modifying DNA sequences. Unlike previous genetic engineering methods, which were laborious and time-consuming, CRISPR can edit genes in a matter of weeks. This makes it a game-changer for researchers, significantly speeding up the pace of genetic manipulation and allowing for more rapid discoveries.

CRISPR is not limited to one type of organism or one specific area of study. It can be used to edit the genomes of bacteria, plants, animals, and even humans, enabling scientists to study a wide range of genetic phenomena and develop targeted therapies for various diseases. Its potential applications are vast, ranging from agriculture and environmental conservation to human health and disease treatment.

Scientists at Gladstone Institutes are working on building the most comprehensive molecular map of the human genome to date, using next-generation CRISPR technology in combination with computational genomics. They are conducting groundbreaking studies, including analyzing the molecular structures that control human T cells, which could help overcome limitations in immunotherapies and identify new drug targets for various conditions, including autoimmune diseases and cancer. The study analyzed over 100,000 sites across nearly 400 genes in functioning human T cells, pinpointing specific nucleotides that influence how immune cells respond to stimuli.

Understanding the functions and interactions of the billions of base pairs in the human genome is key to unraveling the secrets of human biology and developing targeted therapies for diseases. With the advent of next-generation CRISPR technology, scientists now have the tools to systematically edit and analyze the genome, piece by piece, and create a detailed molecular map. This molecular map will provide researchers with invaluable insights into how genes are regulated, how they interact with each other, and how they contribute to disease. By deciphering the complexities of the human genome, we are laying the foundation for a new era of personalized medicine and precision therapies.

Scientists at Gladstone are using computational genomics to analyze the vast amount of data generated from molecular mapping. Through advanced algorithms and machine learning, they can extract meaningful patterns, identify essential genetic signatures, and revolutionize our understanding of the human genome. This collaborative effort brings together scientists, computational biologists, and genetic engineers to build a comprehensive molecular map. The potential rewards of this undertaking are immense, and with this map in hand, researchers will have a wealth of knowledge to delve deeper into the intricacies of human biology and ultimately improve the health and well-being of individuals worldwide.

With the aid of computational genomics and next-gen CRISPR technology, scientists are gaining new insights into human diseases. By mapping the human genome and analyzing gene interactions, researchers can uncover the underlying causes and mechanisms of various diseases, bringing us closer to finding effective treatments and cures. This cutting-edge research has already yielded significant breakthroughs in understanding genetic diseases such as cancer, Alzheimer's, and cardiovascular disorders. By studying the molecular map of the human genome, scientists can identify key genetic mutations or variations that contribute to these diseases, providing invaluable targets for developing personalized treatments.

Computational genomics and CRISPR technology are also shedding light on the complex interplay between genetics and infectious diseases. By studying the genetic variations in pathogens and their interactions with human genes, researchers are uncovering new strategies to combat infectious diseases and develop more effective vaccines. The insights gained from these studies have the potential to transform the field of medicine. By understanding the underlying genetic factors that contribute to disease, doctors can tailor treatments to individual patients, maximize effectiveness, and minimize side effects. Furthermore, the ability to identify genetic predispositions to certain diseases can lead to preventive measures and early interventions, potentially saving lives.

As computational genomics and CRISPR technology continue to advance, we can expect even greater insights into human diseases. This exciting frontier of research is opening up new possibilities for precision medicine, personalized therapies, and ultimately, a healthier future for all.

Accelerating the Pace of Therapeutic Development:

The combination of computational genomics and next-generation CRISPR technology is revolutionizing our understanding of the human genome and significantly speeding up the pace of therapeutic development. By discovering the secrets of human biology, researchers are uncovering new opportunities for targeted treatments and cures for a wide range of diseases.

One of the major benefits of computational genomics and CRISPR is their ability to identify potential therapeutic targets with unprecedented precision. By analyzing the molecular map of the human genome, scientists can pinpoint specific genes or genetic variations that play a crucial role in disease development. This knowledge allows researchers to develop targeted therapies that directly address the underlying causes of the disease, resulting in more effective treatments and better patient outcomes.

Additionally, the speed and efficiency of CRISPR technology are enabling researchers to rapidly test and validate potential therapeutic targets. Traditional drug development processes can be slow and cumbersome, often taking years to bring a treatment to market. However, with the power of computational genomics and CRISPR, scientists can significantly reduce the time it takes to go from identifying a target to developing a potential treatment. This accelerated pace of therapeutic development holds great promise for patients who are in desperate need of new treatments and cures.

In the future, we can expect to see even greater advancements in targeted therapies as computational genomics and CRISPR technology continue to advance. This progress brings us one step closer to personalized medicine, where treatments are tailored to each individual's unique genetic makeup. The possibilities are endless, and the potential for improving human health and well-being is immense.

A Glimpse into the Future of Biomedical Research:

As we look to the future of biomedical research, the possibilities are truly awe-inspiring. The combination of computational genomics and next-generation CRISPR technology has already made remarkable progress in our understanding of the human genome and its implications for human health. But what lies ahead?

In the coming years, we can expect to see even greater breakthroughs in the field of genetics. As computational genomics continues to advance, researchers will be able to analyze larger and more complex datasets, leading to more precise insights into the functions of genes and their interactions. This deeper understanding will pave the way for the development of targeted therapies that can address the underlying causes of diseases with even greater accuracy.

Furthermore, the ongoing refinement of CRISPR technology will enable scientists to edit genes with even more precision and efficiency. This means that the potential for developing personalized medicine and tailored therapies is within reach. The ability to treat individuals based on their unique genetic makeup holds tremendous promise for improving patient outcomes and transforming the field of medicine.

Additionally, the integration of computational genomics and CRISPR technology is likely to lead to the discovery of entirely new therapeutic targets and treatment strategies. By analyzing the intricate molecular map of the human genome, scientists will be able to uncover previously unknown genetic interactions and pathways, opening up new avenues for therapeutic intervention.

The future of biomedical research is incredibly exciting. With computational genomics and CRISPR technology, we are poised to unlock the full potential of the human genome and revolutionize the way we approach disease treatment and prevention. As we continue to unravel the mysteries of human biology, the possibilities are limitless, and the potential for improving human health and well-being is immense. Get ready for a future where precision medicine and personalized therapies become the norm, ushering in a new era of healthcare.

The 2023 Warren Alpert Foundation Prize honors computational biology pioneer David J. Lipman
The 2023 Warren Alpert Foundation Prize honors computational biology pioneer David J. Lipman

The 2023 Warren Alpert Foundation Prize celebrates a frontiersperson in computational biology

Tyler O'Neal, Staff Editor BIOLOGY

Scientist’s vision transformed the way researchers analyze data, access biomedical information

The 2023 Warren Alpert Foundation Prize has been awarded to scientist David J. Lipman for his visionary work in the conception, design, and implementation of computational tools, databases, and infrastructure that transformed the way biological information is analyzed and accessed freely and rapidly around the world. 

The Warren Alpert Foundation bestows the $500,000 award in recognition of work that has improved the understanding, prevention, treatment, or cure of human disease. The prize is administered by Harvard Medical School. 

Lipman will be honored at a scientific symposium on Oct. 11, 2023, hosted by HMS. For further information, visit The Warren Alpert Foundation Prize symposium website. ScienceSource SS2379212 2 0e351

Lipman, who is currently a senior science adviser for bioinformatics and genomics for the Food and Drug Administration, is receiving the award for work he did in the 1980s and 1990s before and after becoming the founding director of the National Center for Biotechnology Information (NCBI), a position he held until 2017.

Lipman led the development of a powerful computational program called BLAST for the analysis and comparison of newly identified DNA and protein sequences against all known DNA and protein sequences. The tool transformed researchers’ ability to access and interpret DNA, RNA, and protein sequence data and propelled the fields of computational biology and molecular biology. While at the NCBI, Lipman also conceptualized and then oversaw the design and implementation of PubMed, the web-based database for biomedical literature used daily by millions of scientists, physicians, students, teachers, and the public. Today, NCBI houses multiple biotechnology databases and resources that, over the years, have reshaped biology, medicine, and other fields of science. 

“At a time when computation was deemed an exotic pursuit by most biomedical researchers, David was prescient because he understood the potential of computation to propel biomedical science forward,” said George Q. Daley, dean of HMS and chair of the Warren Alpert Foundation Prize scientific advisory board. “His vision, creativity, and rigor have transformed how scientists analyze and share data and, indeed, how we do science.” 

Lipman’s pioneering achievements not only democratized access to scientific information but also helped catalyze critical discoveries by enabling vital exchanges and collaborations among scientists in multiple fields of biomedicine and beyond. 

“The foundational work of David Lipman in the field of computational biology and the tools that he envisioned and created have an impact that is nearly impossible to measure on the fields of biology, medicine, and beyond,” said David M. Hirsch, director, and chairman of the board of The Warren Alpert Foundation. “His contributions exemplify the mission and vision of the Warren Alpert Foundation.”

Significance of the work

Over the past 40 years, advances in DNA sequencing, computation, and the internet have transformed biomedical research, public health, and the practice of medicine. Lipman developed many of the most important computational tools and infrastructure for making discoveries with these technologies. 

In the 1980s, as the understanding of DNA and genes accelerated, elucidating the evolutionary relationships across genes and proteins within and between species became a major focus of Lipman’s scientific curiosity and research efforts. Such knowledge is critical in elucidating evolutionary relationships that provide essential clues about the function of genes and proteins.

Early on, Lipman realized that the rapid emergence of new genetic sequencing data would require powerful and efficient computer programs to compare one DNA or protein sequence against all known sequences.

In a series of papers published between 1983 and 1990, Lipman pioneered the design of multiple methods for comparative sequence analysis. This culminated in the development of an algorithm called BLAST, described in a now seminal 1990 paper. Today, BLAST and subsequent programs, gapped BLAST, and PSI-BLAST remain among the most widely used tools in biology and medicine and are deemed among the most significant achievements in the field of computational biology of the past 40 years. 

BLAST enabled understanding of the interplay between genes, biology, physiology, and the environment across organisms and has led to important discoveries in nearly all areas of biomedical research, from the molecular basis of cancer to identify the source of a foodborne outbreak.  

Furthermore, Lipman became one of the most ardent supporters of and key figures in the move toward open-access science. He was instrumental in the design of PubMed, the open-access scientific publication resource of the NCBI and the largest and most widely used resource for scientific research in the world. 

As director of NCBI, Lipman oversaw GenBank, the world’s largest DNA and protein sequence repository, an international collaboration among the United States, Japan, and Europe. Under his direction, NCBI brought GenBank into the era of genomics and the internet, vastly augmenting its capabilities.

“Through the creation of computational tools and information systems, my goal and that of the wonderful collaborators I've had the honor to work with has been to enable biomedical researchers to make discoveries. The scientists involved in the nomination and selection process have a deep understanding of the field and have themselves made some of the most important biomedical discoveries. So, this honor holds a special significance to me,” commented David J. Lipman.

Researchers at The University of Tokyo show how including the effects of the surrounding water during the aggregation of charged particles can improve the accuracy of simulations, which may help elucidate biological self-assembly
Researchers at The University of Tokyo show how including the effects of the surrounding water during the aggregation of charged particles can improve the accuracy of simulations, which may help elucidate biological self-assembly

Japanese prof Tanaka improves the predictions of structures by adding the influence of hydrodynamics to supercomputer simulations of suspended charged particles in solutions including cells

Tyler O'Neal, Staff Editor BIOLOGY

In Tokyo, Japan, investigators from the Institute of Industrial Science at The University of Tokyo added the influence of hydrodynamics, which includes water's flow and compressibility properties, to supercomputer simulations of suspended charged particles in an electric field. They found that this greatly improved the predictions of the final structures compared with conventional computational models. This work may help explain how hydrodynamic interactions impact the self-organization of particles suspended in a solution, including in biological systems like cells.

Brownian dynamics (BD) simulations, in which a computer predicts the motion of randomly diffusing particles based on the forces they exert on each other, have greatly improved our understanding of how the material can self-assemble out of smaller parts. However, for the sake of keeping the computational cost manageable, the calculations must usually be simplified. Unfortunately, these approximations sometimes give rise to misleading results.

Now, a team of researchers at The University of Tokyo has demonstrated that simplifying calculations by neglecting the effects of the water hydrodynamics for particles in an aqueous solvent can give rise to inaccurate results. In particular, they show that if the particles are charged and experiencing an external electric field, the final arrangement of self-assembled structures depends on the ability of the solvent water to flow. This is an example of a colloid, a type of mixture in which insoluble particles are suspended in a liquid. This system can assume a semisolid gel state if the particles aggregate to form tendrils that span the entire volume of the sample. “Colloidal self-assembly is a promising bottom-up strategy to create higher-order structures from the elementary building blocks,” says first author Jiaxing Yuan.

The fact can explain the importance of accounting for hydrodynamics that the solvent must flow into the gap between the particles to allow them to separate. The team termed this effect the “inverse squeezing flow” effect because it is the opposite of the squeezing out of the solvent that occurs during colloidal aggregation. The result is that the colloidal particles form clusters with branching tendrils that can form a gel. Conversely, simple BD simulations incorrectly predicted that bundle-like linear aggregates of linear chains would be formed. “Our findings indicate that including hydrodynamics allows us to better predict the pathway of self-assembly, which may lead to the production of soft materials with properties, such as gel stiffness, that can be controlled with an external electric field,” explains the senior author, Hajime Tanaka. This work may lead to the development of smart materials that respond to external conditions, either during manufacturing or in response to changing environments, such as a soft gel that hardens when desired.